Rhythm

AccurKardia Named a Rising Star Winner at the 2026 Digital Health Hub – Digital Health & AI Awards at HLTH USA

NEW YORK–(BUSINESS WIRE)– #Awards–AccurKardia, an ECG-led diagnostics software company, today announced that it has been named a winner at the 2026 Digital Health & AI Awards, presented by the Digital Health Hub Foundation at HLTH USA 2026 in Las Vegas. AccurKardia is one of three Rising Star winners in the Cardiometabolic, Obesity & Diabetes category. The Foundation selected 38 winners from more than 1,300 participating companies worldwide and announced them on November 16 at its Awards Grand

AliveCor and PulseAI Partner to Bring Advanced Cardiac AI Determinations and Clinical Care Platform to Major Consumer Wearables

FDA-cleared PulseAPI SmartWatch integration adds Premature Ventricular Contraction (PVC) detection to Apple Watch and cuts inconclusive ECG readings by 92%, easing clinical review burden PulseAI’s algorithmic engine also supports ECG rhythm determinations across Samsung, Withings, and Fitbit devices MOUNTAIN VIEW, Calif. & BELFAST, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) — AliveCor, the global leader in AI-powered cardiology, and PulseAI, a pioneer in artificial intelligence software for electrocardiogram (ECG) analysis, today announced a strategic partnership to expand clinical-grade cardiac care across mainstream consumer wearables. Leveraging PulseAI’s recent U.S. Food and Drug Administration (FDA) 510(k) clearance for PulseAPI SmartWatch, the collaboration will bring AI rhythm determinations to compatible third-party wearables for users with a KardiaCare subscription via the Kardia App. Most notably, the partnership will offer advanced detection of sinus rhythm with PVCs for Apple Watch customers. This new capability will seamlessly help convert personal wearable data into actionable clinical consultations and specialist overreads, helping close a long-standing gap in consumer wearable diagnostics. “Consumer wearables have successfully fostered personal wellness, but the real breakthrough lies in turning daily tracking into clinically actionable data,” said Priya Abani, CEO of AliveCor. “Heart disease remains the leading global health challenge, and by democratizing access to medical-grade insights and cardiovascular specialists at scale, we can detect conditions earlier, improve outcomes, and save more lives.” “We are excited to announce our first partnership for our AI ECG technology,” said Dr Alan Kennedy, CEO of PulseAI. “Our mission is to make advanced ECG analysis accessible to as many patients as possible. Partnering with AliveCor brings us closer to that goal by connecting the wearable devices people already use with meaningful heart rhythm insights and clinical care.” Clinical-Grade AI for Leading WearablesThe PulseAPI SmartWatch platform acts as an intelligent software library that processes and analyzes Lead I data from compatible wearable devices. Under the FDA clearance, the algorithms deliver automated noise filtering, heart rate measurement, and targeted rhythm classification: Advanced Capabilities for Apple Watch Users: When processing Lead I data from compatible Apple Watch hardware, the platform delivers rhythm analysis for sinus rhythm, atrial fibrillation (AFib), bradycardia, and tachycardia. Critically, it provides beat-by-beat QRS detection to identify normal sinus rhythm versus sinus rhythm with PVCs, classifies individual beats as sinus rhythm with PVC or non-PVC.Broad Consumer Ecosystem Support: PulseAI’s FDA-cleared algorithmic engine supports ECG rhythm determinations (detecting sinus rhythm, AFib, noisy recordings, and average beat calculation) across leading consumer wearables and monitors, including Samsung Galaxy Watch, Fitbit Sense, and Withings ScanWatch. While consumer wearables have traditionally alerted users to basic rhythm abnormalities, this partnership transforms isolated data into meaningful context for healthcare providers. In Apple Watch, beyond expanding rhythm classifications, the technology directly tackles one of the largest bottlenecks in digital cardiology: the administrative and clinical burden created by inconclusive ECGs, which often trigger manual reviews, repeat recordings, and unnecessary follow-ups. In a prospective study of 296 participants published in Heart Rhythm, PulseAI’s algorithm improved AFib detection sensitivity while delivering a 92% reduction in inconclusive interpretations compared to the Apple Watch’s native algorithm—enabling clinical teams to manage higher recording volumes with existing resources. Advanced determinations from the AliveCor and PulseAi partnership will be available on select, compatible third-party devices including Apple Watch, Samsung Galaxy Watch, Fitbit Sense, and Withings ScanWatch in the first half of 2027. For more information contact press@alivecor.com. About AliveCorAliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) devices, is transforming cardiology with its medical-grade AI solutions. The company was named to the TIME World’s Top HealthTech Companies list for the second consecutive year in 2026—recognition of its commitment to delivering innovative devices and services that empower patients and physicians with personalized, actionable heart data. With over 400 million ECGs recorded, the company’s Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds. The company’s latest offering, Kardia 12L ECG System, powered by KAI 12L cleared to detect 39 cardiac conditions (with determination availability varying by geography), was designed exclusively for use by healthcare providers. AliveCor’s enterprise platform allows third-party providers to manage their patients’ and customers’ heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas. AliveCor is a privately held company headquartered in Mountain View, Calif. For more information, visit alivecor.com and follow us on LinkedIn, X, Instagram and Facebook. About PulseAI PulseAI, founded in 2020, is based in Belfast, Northern Ireland. The company has developed deep learning algorithms trained on millions of ECGs to deliver clinically validated performance across smartwatches, patches, hospital monitors, and defibrillators. For more information, visit www.pulseai.io and follow us on LinkedIn and X (Twitter). Media Contacts Alivecor Morgan MathisDirector of Corporate Communications, AliveCorpress@alivecor.com Pulse AIAlan KennedyCEO and Founder, PulseAIalan.kennedy@pulseai.io

Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology

KIRKLAND, Wash., Nov. 16, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced publication of primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS) in the Journal of Cardiovascular Electrophysiology. The largest prospective real-world study of wearable cardioverter defibrillators (WCD) to date, ACE-PAS enrolled 21,612 patients across 35 U.S. states and met both primary safety and effectiveness endpoints. The study demonstrated 100% all-shock conversion success and sustained daily wear, while documenting ventricular arrhythmias early and continuously over subsequent months. The findings strengthen the clinical case for the ASSURE system across WCD indications and underscore the importance of protecting patients throughout periods of elevated arrhythmic risk. “Advances in medical therapy have improved cardiac recovery after a myocardial infarction or a new heart failure diagnosis, but the recovery period can leave patients vulnerable to life-threatening ventricular arrhythmias,” said Jeanne E. Poole, MD, Professor of Medicine at the University of Washington and Principal Investigator. “ACE-PAS confirmed the early risk of ventricular tachycardia and ventricular fibrillation (VT/VF) and demonstrates why WCD protection matters: it provides an opportunity to prevent sudden cardiac death while giving patients time to recover.” The publication provides a full report of findings first presented as late-breaking science at the American Heart Association Scientific Sessions 2025, along with additional analyses of arrhythmic risk. Key findings include: 100% all-shock conversion   ASSURE WCD successfully converted all 303 analyzable VT/VF shock events with one or more shocks, meeting the primary effectiveness endpoint.  Primary safety endpoint achieved  The inappropriate-shock rate was 0.0065 per patient-month, outperforming the prespecified safety performance goal. 94% of patients experienced no false-positive shock alarms The low alarm burden supports a better patient experience and helps enable the sustained wear needed for continuous protection. 23.1 hours of median daily wear—even beyond 90 days Patients wore ASSURE for a median of 23.1 hours per day.30% continued use beyond 90 days while maintaining the same median daily wear time, highlighting ASSURE’s practicality in real-world, long-term care. VT/VF risk persisted beyond the first month 2.6% of patients experienced at least one shocked or unshocked VT/VF event. While 55% of episodes occurred during the first month, events continued in subsequent months—reinforcing the need for protection throughout the prescription period. Meaningful arrhythmic risk extended across major etiologies Among patients with LVEF ≤35% who met primary-prevention criteria for sudden cardiac death, the estimated risk of experiencing VT/VF within 90 days was 3.2% following myocardial infarction, 2.8% in ischemic cardiomyopathy and 2.5% in nonischemic cardiomyopathy.   “Publication of the ACE-PAS results marks an important milestone in advancing the evidence base for wearable defibrillator therapy and monitoring,” said Brian Webster, President and CEO of Kestra Medical Technologies. “Real-world evidence at this scale reinforces confidence in the ASSURE system and strengthens the clinical foundation for protecting patients during recovery. We will continue to build on these insights to give providers more ways to protect at risk patients.” Drawing on ACE-PAS data, Kestra introduced an enhanced detection algorithm in April 2026 for the ASSURE WCD that further reduces the already low false-positive alarm burden while maintaining VT/VF detection sensitivity. With the enhanced algorithm, the inappropriate shock rate is projected to decrease by nearly 70%, from 0.0065 to 0.0020 per patient-month.1, 2 The peer-reviewed publication, “Real-World Performance of a Novel Wearable Cardioverter-Defibrillator System: Primary Results From a National Prospective Post-Approval Registry Study (ACE-PAS),” is available at http://doi.org/10.1111/jce.70556 About ACE-PASThe ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) was an FDA-mandated, prospective, single-arm post-approval registry evaluating the safety and effectiveness of the ASSURE Wearable Cardioverter Defibrillator in routine clinical use. Funded by Kestra, the study included 21,612 patients fitted between November 2021 and July 2025. Primary endpoints were all-shock VT/VF conversion success and inappropriate-shock incidence, evaluated against prespecified performance goals. About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.  Forward-Looking StatementsThis press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. For a discussion of factors that could cause actual results to differ, see Kestra’s filings with the U.S. Securities and Exchange Commission. Kestra undertakes no obligation to update any forward-looking statements except as required by law. Finch D, et al. Research Square. April 22, 2026. Preprint.Poole JE, et al. Circulation. 2025;152:e526–e605. CONTACT: Media contact 
Rhiannon Pickus 
rhiannon.pickus@kestramedical.com 

Investor contact 
Neil Bhalodkar 
neil.bhalodkar@kestramedical.com 

Adagio Medical Provides Business Update: 22 Patients Treated with Next-Generation vCLAS™ Ultra System as FULCRUM-VT IDE Sub-Study Advances

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today provided a business update highlighting continued execution of its FULCRUM-VT IDE study and FULCRUM-VT IDE sub-study, as well as progress of its previously announced review of strategic alternatives. Clinical Update To date, the Company has treated a total of 22 patients with the Com

CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama

ANTONY, France–(BUSINESS WIRE)–CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable d

Esperto medical logo

Esperto Medical Awarded Grant by the Translational Research Institute for Space Health (TRISH) to Advance Noninvasive Monitoring Technology for Spaceflight

Esperto Medical’s Resonance Sonomanometry™ technology will be developed to enable continuous, calibration-free cardiovascular monitoring for terrestrial environments and spaceflight. FULLERTON, Calif., Nov. 6, 2026 /PRNewswire/ — Esperto Medical, Inc., a healthtech startup specializing…